Amy Criego, Anders L Carlson, Sue Brown, Gregory P Forlenza, Bruce Bode, Carol Levy, David Hansen, Irl B Hirsch, Richard M Bergenstal, Jennifer L Sherr, Sanjeev Mehta, Lori Mb Laffel, Viral N Shah, Anuj Bhargava, Ruth S Weinstock, Sarah A MacLeish, Daniel J DeSalvo, Thomas C Jones, Grazia Aleppo, Bruce A Buckingham, Trang T Ly
BACKGROUND: The Omnipod® 5 Automated Insulin Delivery (AID) System was shown to be safe and effective following 3 months of use in people with type 1 diabetes (T1D); however, data on the durability of these results are limited. This study evaluated the long-term safety and effectiveness of Omnipod 5 use in people with T1D during up to 2 years of use. METHODS: After a 3-month single-arm, multicenter, pivotal trial in children (6-13.9y) and adolescents/adults (14-70y), participants could continue system use in an extension phase...
October 18, 2023: Diabetes Technology & Therapeutics